Oculis Holding AG
oculis.comWhat Do They Do?
Develops eye drops and other drug candidates for people with retinal, dry-eye and optic-nerve diseases.
20-F for FY2025, filed Mar 4, 2026Switzerland, the U.S. and Iceland. We have substantial expertise in therapeutics for the treatment of neuro-ophthalmic and ophthalmic…View ↗
Our pipeline currently includes three clinical-stage therapeutic candidates: OCS-01, Licaminlimab (OCS-02) and Privosegtor (OCS-05).…View ↗
Developed from our proprietary technology, OCS-01 is an OPTIREACH® formulation of high-concentration dexamethasone. It is being developed…View ↗
We are also advancing the clinical development of Licaminlimab, a next-generation biologic treatment for ocular inflammation, specifically…View ↗
Privosegtor, a novel small molecule peptoid that penetrates the blood-brain and retinal barriers and was selected by high-throughput…View ↗
How Are They Changing?
Broader disease focus
The earlier report described development for ocular diseases, including surgery-related inflammation and pain, uveitis, glaucoma, diabetic retinopathy and neurotrophic keratitis. The latest report centers on neuro-ophthalmic and ophthalmic diseases, with candidates for dry eye and optic-nerve conditions.
20-F for FY2022, filed Mar 28, 2023 20-F for FY2025, filed Mar 4, 2026We are a clinical-stage biopharmaceutical company, based in Switzerland, with substantial expertise in therapeutics used to treat ocular…View ↗
Our focus is on advancing therapeutic candidates intended to treat significant ophthalmic diseases which result in vision loss, blindness…View ↗
We are also advancing the clinical development of OCS-02, a next-generation biologic treatment for both DED and non-infectious chronic…View ↗
Switzerland, the U.S. and Iceland. We have substantial expertise in therapeutics for the treatment of neuro-ophthalmic and ophthalmic…View ↗
We are also advancing the clinical development of Licaminlimab, a next-generation biologic treatment for ocular inflammation, specifically…View ↗
Privosegtor, a novel small molecule peptoid that penetrates the blood-brain and retinal barriers and was selected by high-throughput…View ↗
Who Do They Compete With?
Competes with Abbvie, ANI Pharmaceuticals, Bayer, Novartis, Regeneron, Roche, Alcon, Bausch + Lomb, Viatris, Harrow, Sun Pharmaceuticals, Amgen, Dompé, Argenx, and Veridian
20-F for FY2025, filed Mar 4, 2026Several large pharmaceutical and biopharmaceutical companies that have commercialized, or are developing treatments for ocular diseases…View ↗
Loading...
